ELTP News 0.3150 08/26/2014 04:57:39 Elite Pharma Inc (ELTP)

New Post Public Reply Private Reply Replies (0) Message Board

Aug 26, 2014 at 5:57 AM

Elite Pharma Inc (ELTP) 0.3150 $ELTP

OTC Daily Trading News: Evoq Properties, Inc. MedBox, Inc. LabStyle Innovations Corp, MyEcheck, Inc. Elite Pharmaceuticals, Inc.
PR Newswire Europe - Tue Aug 19, 10:11AM CDT
LONDON, August 19, 2014 /PRNewswire/ --

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
GlobeNewswire - Thu Aug 14, 3:14PM CDT
Revenues Increase by 61%, Product Development on Schedule

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
GlobeNewswire - Wed Aug 13, 6:09AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide a quarterly business update at 11:00 AM ET on Monday, August 18, 2014. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals reports launch of pivotal bioequivalence study of ELI-201 in healthy volunteers to address issues in prescription drug abuse
M2 - Wed Jul 16, 9:08AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) disclosed on Tuesday the dosing of the first volunteer in a pivotal bioequivalence study of ELI-201 utilising its proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
GlobeNewswire - Tue Jul 15, 10:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating

Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer.

OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.

Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.

Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY

Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.

Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions.

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

("Elite"

(OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
GlobeNewswire - Fri Feb 14, 8:49AM CST
Revenues Increase by 154%, Product Development Accelerating

Prolexic Publishes Infographic on Largest Attacks Mitigated in 2013
M2 - Fri Feb 14, 8:07AM CST
Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today published a new infographic summarizing the statistics about the largest DDoS attacks it mitigated in each quarter of 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bybit Expands ByPick Game with Broader Market Reach

Bybit Plays the Game of Expansion Step right up to Bybit’s latest offering – ByPick Season 2. Some folks might be scratching their heads about what's shifting in this free-to-play space, but here we are, watching a beast that’s a mix between a carnival game and a hedge fund playpen. No money exchanged, just knowledge on the line. That's right, we're diving into a...

Cemig and Huawei's Bold Network Leap: Power Up

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

OI Investors Crack Down: Class Action Filing Looms

O-I Glass Under Fire: The Glass Containers Giant Stumbles If you’ve been watching the ticker for O-I Glass, Inc. (NYSE:OI), you know it’s been a rocky road lately. We’re knee-deep in another saga of corporate promises meeting harsh reality. The novel here isn’t just the $1 trillion industry O-I Glass plays in, but the speed at which its fortunes seem to be...

DEEPBLUE's Panelized Systems Target Low-Rise Markets

Changing the Game in Low-Rise Construction Been around the block a few times and seen all sorts of hype in this industry, but what DEEPBLUE SMARTHOUSE is pushing sounds more like evolution than revolution for low-rise builds. They're leaning into this panelized building system like a boxer on the ropes—that's their strategy to keep things steady and predictable. The...

TagMaster To Acquire Kapsch's RFID Ops in NA Market

A Strategic Move in the Transportation Sector Here's a fresh shake-up for the North American transportation sector: TagMaster, alongside its U.S. subsidiary Sensys Networks, is all set to acquire Kapsch TrafficCom's RFID-focused North American components business. This isn't just a minor shuffle—this deal could ripple through the industry, promising strategic uplifts...

SDI's Bhatt Celebrates Back-to-Back Chicago Titan Wins

Second Year in a Row: A Nod to Visionary Leadership Hot off the press, folks. Hardik Bhatt, steering the ship at SDI Presence, is basking in the glory of a repeat recognition as a Chicago Titan 100 honoree. It's not just a headline; it's a testament to Bhatt's leadership prowess and how he plays the IT consultancy game. This isn't your run-of-the-mill award, but a salute...

Cuisine.K Brings Korean Seafood to Seattle Spotlight

Korean Seafood Makes Waves in Seattle Bring out the chopsticks, ‘cause Korean seafood just took Seattle by storm with the Cuisine.K Korean culinary showcase. Hosted by CJ Foods, alongside the Korea Fisheries Association, this event smacked the local food scene square in the face with the unique flavors and techniques of K-Seafood—from students all the way to seasoned...

Procon Uses Robotics to Revamp Cruise Terminal 5

Building Bigger with Robotics at Port Canaveral Robots on a construction site sounds like sci-fi, right? But it's the reality at Port Canaveral's Cruise Terminal 5, where Procon is rolling out its robotic tech magic. This ain't your everyday wrench-and-spanner job; we're talking remote-controlled bots capturing 360-degree images. “Regular reality capture can help teams...

AI Use Hits 93% in Health Systems' Digital Shift

Healthcare's AI Surge: Jumping the Adoption Hurdle The digital health landscape isn't just humming along—it's hitting high gear. AI, once the shiny toy in innovation's toolkit, is now a fixture in 93.2% of healthcare systems according to CHIME's latest findings. For anyone keeping score, that's a hefty leap and paints a picture where AI isn't just in the game, it's...

Xavier Ochsner Opens State-of-the-Art Medical School

A New Era for Medical Education in New Orleans If you're familiar with New Orleans, you know it's a city defined by its vibrancy, culture, and resilience. Well, the Xavier Ochsner College of Medicine is adding to that narrative with the opening of their spanking new Center for Medical Education. It's a project that promises to shake things up in the best possible way for...